Contrasting AC Immune (NASDAQ:ACIU) & Kyntra Bio (NASDAQ:KYNB)

AC Immune (NASDAQ:ACIU – Get Free Report) and Kyntra Bio (NASDAQ:KYNB – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AC Immune and Kyntra Bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune 1 1 2 1 2.60
Kyntra Bio 1 1 5 0 2.57

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 252.11%. Kyntra Bio has a consensus target price of $36.80, suggesting a potential upside of 969.77%. Given Kyntra Bio’s higher probable upside, analysts clearly believe Kyntra Bio is more favorable than AC Immune.

Volatility & Risk

AC Immune has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Earnings & Valuation

This table compares AC Immune and Kyntra Bio”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AC Immune $4.31 million 50.29 -$85.03 million ($0.50) -4.26
Kyntra Bio $4.62 million 3.02 $183.45 million $45.30 0.08

Kyntra Bio has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AC Immune and Kyntra Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AC Immune -181.38% -105.25% -25.04%
Kyntra Bio 2,199.13% N/A -47.27%

Institutional & Insider Ownership

51.4% of AC Immune shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kyntra Bio beats AC Immune on 9 of the 15 factors compared between the two stocks.

About AC Immune

(Get Free Report)

AC Immune SA is a Swiss biopharmaceutical company focused on developing precision medicines and diagnostic products for neurodegenerative diseases. Its research programs address conditions including Alzheimer’s and Parkinson’s diseases, as well as other neurological disorders. The company’s pipeline includes immunotherapies and small-molecule drug candidates designed to target proteins associated with neurodegeneration. AC Immune also develops diagnostic approaches and uses proprietary technology platforms, including SupraAntigen and Morphomer, to identify and advance potential treatments.

About Kyntra Bio

(Get Free Report)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.